EyePoint, Inc. 8-K

What Happened

• On March 20, 2026, EyePoint, Inc. filed a complaint in the Middlesex County Superior Court (Commonwealth of Massachusetts) against Ocular Therapeutix, Inc. The complaint alleges Ocular Therapeutix disseminated false or misleading statements about EyePoint and the clinical results for EyePoint's lead product candidate, DURAVYU™ (vorolanib intravitreal insert). EyePoint asserts causes of action including defamation, commercial disparagement, violations of Mass. Gen. L. c. 93A (consumer protection statute), and tortious interference.

Key Details

• Filed: March 20, 2026 (Complaint submitted to Middlesex County Superior Court, MA)
• Defendant: Ocular Therapeutix, Inc.
• Product referenced: DURAVYU™ (vorolanib intravitreal insert), EyePoint’s lead product candidate
• Claims/Relief sought: defamation, commercial disparagement, violations of Mass. Gen. L. c. 93A §§2 & 11, tortious interference; seeking injunctions (stop further dissemination, public retraction), monetary damages, attorneys’ fees and costs

Why It Matters

• This filing notifies investors of a formal legal dispute that alleges reputational and commercial harm tied to public statements about EyePoint’s clinical data. Potential outcomes (injunctions, damages, retractions) could affect the company’s public messaging and competitive environment, and litigation can involve legal costs and management attention. EyePoint disclosed this under Item 7.01 (Regulation FD Disclosure); investors should watch for further 8-K updates or court filings for developments and any financial impact.